DETROIT HEALTH DEPARTMENT
UM HMP Opioid Project
Taylor, Mariam, Zakiya, Jordan, Marina
Meeting Agenda

→ Project Objectives
→ Completed Work to Date
→ Issue Tree & Drivers
→ Preliminary Findings
→ Plan of Action Going Forward
→ Preliminary Recommendations
→ Questions, Feedback, & Discussion
Project Objectives

01 State of Buprenorphine Access

02 Best Practices

03 Policy Recommendations
Completed Work to Date

- Background Research
- Issue Tree & Driver Diagram
- Interview Protocol
- Interviews (12+ completed to date)
  - Contacted Detroit SAMHSA certified Buprenorphine providers
  - Spoke with Michigan Opioid Collaborative to find more interviewees
  - Contacted 30+ local government agencies, FQHCs, addiction experts, PCPs
Preliminary Findings Based on Interviews: **Barriers**

**Provider Perspective**

#1: Not identified as a community need  
#2: Prior authorization requirements  
#3: Stigma (pt. population, risk of diversion)  
#4: Cost  
#5: Insufficient training

**Community Health Center Perspective**

#1: Not identified as a community need  
#2: Prior authorization requirements  
#3: Stigma (risk of diversion)  
#4: Cost
Preliminary Findings Based on Interviews: Facilitators

Buprenorphine

Cost
Enrollment in 340B Drug Discount Program and other HRSA grants

Prior Authorization
Waived for many privately insured patients and at certain institutions (VA)

Discussion Forums
I.e. Project ECHO; multidisciplinary conversations

Relationships with Larger Healthcare Systems

Other Treatment Options
Utilization of other MAT (Naltrexone) and other treatment options
Preliminary Recommendations:

**Problem**
- Stakeholders: See minimal/no need for Buprenorphine
- Stakeholders: Unaware of access problems
- Patients: Not requesting Buprenorphine
- Legislators: Lack of data & information

**Recommendation**
- Share findings with community to facilitate discussion
- Advocate for elimination of prior authorization
Plans Going Forward

Primary Research

→ Complete interviews
→ Follow up with non-respondents

Literature Review

→ Review of local laws and guidelines regarding Buprenorphine
→ Assess best practices and innovative solutions from other jurisdictions

Compile and Code Findings

→ Compile and code responses by respondent type
→ Focus: barriers, facilitators, and solutions
Thank You!

Questions
Thoughts
Feedback